Your session is about to expire
← Back to Search
tenofovir alafenamide for Liver Disease
Summary
The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical questions regarding the management of CHB by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to antiviral treatments used in clinical practice.
- Liver Disease
- Hepatitis B
- Hepatitis
Timeline
Treatment Details
Trial Design
Find a Location
Who is running the clinical trial?
Share this study with friends
Copy Link
Messenger